Pioglitazone Versus Glimepiride on Coronary Artery Calcium Progression in Patients With Type 2 Diabetes Mellitus A Secondary End Point of the CHICAGO Study

作者：Davidson Michael H^*; Beam Craig A; Haffner Steven; Perez Alfonso; D'Agostino Ralph Sr; Mazzone Theodore

来源：Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30(9): 1873-1876.

DOI：10.1161/ATVBAHA.110.207696

• atherosclerosis
• diabetes mellitus
• insulin resistance
• lipoproteins
• coronary artery calcium

Objective-To compare coronary artery calcium (CAC) progression between 2 treatment groups, pioglitazone versus glimepiride.
Methods and Results-The CHICAGO (Carotid Intima-Media Thickness in Atherosclerosis Using Pioglitazone) study demonstrated that pioglitazone significantly decreased carotid intima-media thickness progression compared with glimepiride in patients with type 2 diabetes mellitus. The CAC level was determined at baseline and at the end of 72 weeks of treatment in the pioglitazone (n=146) and glimepiride (n=153) treatment groups using electron beam computed tomography. There was no difference in CAC progression between the treatment groups. By using backward and forward selection models, age, race/ethnicity, and baseline apolipoprotein B level predicted CAC progression. There was no relationship between carotid intima-media thickness and CAC progression during the study.
Conclusion-There was no difference in CAC progression in patients with type 2 diabetes mellitus treated with pioglitazone or glimepiride. Age, race/ethnicity, and baseline apolipoprotein B level predicted CAC progression in patients with type 2 diabetes mellitus. (Arterioscler Thromb Vasc Biol. 2010;30:1873-1876.)

• 出版日期2010-9